P2Y12 is a chemoreceptor for adenosine diphosphate (ADP) [5][6] that belongs to the G i class of a group of G protein-coupled (GPCR) purinergic receptors. [7] . This P2Y receptor family has several receptor subtypes with different pharmacological selectivity, which overlaps in some cases, for various adenosine and uridine nucleotides.

The objectives of this review are to discuss the pharmacological limitations of the P2Y12 inhibitor clopidogrel, and describe the novel alternative P2Y12 inhibitors prasugrel and ticagrelor and the clinical implications of the introduction of these new medicines.

To determine the degree of platelet inhibition from the use of P2Y12 inhibition drug therapies known as thienopyridines. These include Clopidogrel (Plavix), Prasugrel, Ticlopidine (Ticlid), and Ticagrelor.

Jul 14, 2024 · Antiplatelet medicines work to make your platelets less sticky and thereby help prevent blood clots from forming in your arteries. Aspirin is an antiplatelet medicine that may be used. P2Y12 receptor blockers are another group of antiplatelet medicines.

The platelet P2Y12 receptor (P2Y12R) for adenosine 5'diphosphate (ADP) plays a central role in platelet function, hemostasis, and thrombosis. Patients with inherited P2Y12R defects display mild-to-moderate bleeding diatheses.

Platelet activation during disease states leads to vascular occlusion and ischemic damage. The P2Y 12 receptor, activated by ADP, plays a central role in platelet activation and is the target of P2Y 12 receptor antagonists that have proven therapeutic value.

P2Y12 is a G-protein-coupled receptor that is activated upon ADP binding. Considering its well-established role in platelet activation, blocking P2Y12 has been used as a therapeutic strategy for antiplatelet aggregation in cardiovascular disease ...

Oct 30, 2017 · Dual antiplatelet therapy with aspirin and a P2Y 12 inhibitor is the treatment of choice for the prevention of atherothrombotic events in patients with acute coronary syndromes and for those undergoing percutaneous coronary interventions.

P2Y receptors are G-protein-coupled receptors (GPCRs) for extracellular nucleotides. The platelet ADP-receptor which has been denominated P2Y 12 receptor is an important target in pharmacotherapy.

The P2Y12 is an ADP receptor in platelets, which is an essential part of platelet activation (Hechler and Gachet, 2015). Stimulation of P2Y12 by ADP, which is released from dense granules of activated platelets, results in sustained platelet aggregation and secretion (Jin and Kunapuli, 1998).